HLB Panagene KRX:046210KOSDAQ

HLB파나진 · Korean news coverage and regulatory filings, organized.

Articles, 24h0
Articles, 7 days16
DART filings, 7 days1
Articles tracked55since Sep 11

In Q3 2026, HLB Panagene reported revenue of ₩3.5bn, down 2.6% year on year, and an operating loss of ₩141m. HLB Panagene (HLB파나진) appeared in 16 Korean news articles and 1 DART filing over the past seven days. Coverage peaked on Nov 11 with 16 articles. The most common catalyst was clinical & approvals (6).

Filing signals 4 quarters of losses Screener

HLB Panagene today: up or down?

No sign-up, one tap a day. These numbers show what visitors think and are not investment advice.

Upcoming dates as filed

  • Nov 16 Quarterly report filing deadlinetoday · period ending Sep 2026

Dates HLB Panagene stated in its DART filings. A conversion period opening does not mean new shares appear that day; bondholders must request conversion.

HLB Panagene quarterly results consolidated, KRW

QuarterRevenueYoYOperating profitNet income
Q3 2026₩3.5bn-2.6%−₩141m
margin −4.0%
−₩989m
Q2 2026₩3.7bn+1.9%−₩158m
margin −4.3%
₩1.6bn
Q1 2026₩3.1bn-11.6%−₩749m
margin −23.9%
−₩1.1bn
Q4 2025 derived₩4.2bn+21.9%−₩1.7bn
margin −39.6%
−₩3.6bn
Q3 2025₩3.6bn-5.6%−₩829m
margin −22.8%
−₩164m
Q2 2025₩3.6bn+47.7%−₩200m
margin −5.5%
₩1.2bn
Q1 2025₩3.5bn+3.9%−₩733m
margin −20.7%
−₩584m
Q4 2024 derived₩3.5bn+30.8%−₩270m
margin −7.8%
₩1.1bn

HLB Panagene ranks #1511 of 2,345 Korean listed companies by Q3 2026 operating profit. Q3 2026 Korean earnings rankings →

Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.

HLB Panagene top stories 2 weeks, by number of outlets

  1. 1
    HLB Panajin receives HPV diagnostic product approval in Mexico
    9 outlets · 9 articlesFirst report Nov 11 09:01 뉴스핌
  2. 2
    HLB Panazine acquires HPV molecular diagnostic product approval in Mexico
    3 outlets · 3 articlesFirst report Nov 11 09:27 히트뉴스Regulatory approval
  3. 3
    HLB Panagene obtains HPV molecular diagnostic approval in Mexico, targets Central and South America IVD market
    1 outlets · 1 articlesFirst report Nov 11 09:21 이투데이Regulatory approval
  4. 4
    HLB Panagin gains Mexico approval for HPV diagnostic kit, expanding Central and South America foothold
    1 outlets · 1 articlesFirst report Nov 11 09:43 한국면세뉴스
  5. 5
  6. 6
    HLB Panagene obtains HPV diagnostic kit approval in Mexico
    1 outlets · 1 articlesFirst report Nov 11 09:32 PRESS9

Latest HLB Panagene news Korean headlines